New Drug Combo Potentially Practice Changing in Advanced HCC New Drug Combo Potentially Practice Changing in Advanced HCC
Atezolizumab plus bevacizumab was superior to sorafenib for maintaining quality of life in patients with unresectable hepatocellular carcinoma (HCC).Medscape Medical News
Conditions: Carcinoma, Hepatocellular; Biliary Tract Cancer; Secondary Liver Cancer; Liver Metastases Interventions: Drug: RO7119929; Drug: Tocilizumab Sponsor: Hoffmann-La Roche Not yet recruiting
Purpose of review This review will describe the natural history of alcohol-related liver disease (ArLD) in light of recent data that have synthesized existing knowledge on this topic and described new research cohorts to improve our understanding of progression and outcomes in ArLD. Recent findings ArLD occurs after a threshold of alcohol consumption, but this threshold is lowered by the presence of comorbid factors of which obesity is the most common. The most common stage of ArLD is alcohol-related steatosis: this is associated with a low rate of progression to cirrhosis (3%/year) and nonliver-related morbidity is m...
Purpose of review Despite major therapeutic improvements in most cancer entities, hepatocellular carcinoma (HCC) has remained a dismal disease. In fact, incidence and mortality are increasing in many parts of the world, including the United States. Given that a number of systemic agents has recently been tested positive in phase 3 clinical trials, the objective of this review is to summarize the current treatment landscape for advanced HCC. Recent findings Following the positive SHARP trial in 2008, sorafenib has been the only systemic agent for advanced HCC for almost a decade. However, in first line, lenvatinib was ...
Publication date: Available online 8 April 2020Source: Pharmacological ResearchAuthor(s): Yanan Gao, Xing Fan, Nan Li, Chengzhi Du, Bin Yang, Wenhao Qin, Jing Fu, Geoffrey J. Markowitz, Hongyang Wang, Jianli Ma, Shuqun Cheng, Pengyuan Yang
This study focused on toxicities, cellular oxidative stress, adherence, and quality of life of 11 patients with HCC treated with sorafenib. Dermatotoxicity, myelotoxicity, gastro toxicity, nephrotoxicity, pain, and fatigue were investigated. For oxidative stress analysis, the peripheral blood mononuclear cells were isolated and mitochondrial superoxide anion production was measured using MitoSOX Red test. Medication adherence was evaluated based on Morisky-Green and MedTake tests. Quality of life assessment was performed using EORTC QLQ C-30 and QLQ HCC18 questionnaires. The results showed that hand-foot syndrome (45.5%), ...
Publication date: Available online 7 April 2020Source: Annals of Medicine and SurgeryAuthor(s): Hazem M. Zakaria, Mahmoud Macshut, Nahla K. Gaballa, Ahmed E. Sherif, Mohammed E. Abdel-Samea, Mohamed Abdel-Samiee, Ibrahim Marwan, Taha Yassein
British Journal of Cancer, Published online: 08 April 2020; doi:10.1038/s41416-020-0817-7Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma
This study demonstrated that trillin could dramatically inhibit hepatoma carcinoma cell proliferation, induce apoptosis and decrease migration and invasion through suppressing phosphorylated STAT3 translocated to nucleus. Trillin could down-regulate Bcl-2 and Survivin, up-regulate cleaved PRAP, leading to dramatically apoptosis; trillin could also down-regulate MMP1, MMP2, MucI and VEGF, which displayed an inhibition effect on hepatocellular tumor cells invasion and development. The results of this study indicated the potential utility of trillin as a STAT3 inhibitor for the treatment of cancers.
Publication date: Available online 6 April 2020Source: Journal of Geriatric OncologyAuthor(s): Sukeshi Patel Arora, Snegha Ananth, Norma Ketchum, Jonathan Gelfond, Joel Michalek, Devalingam Mahalingam